Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*
September 17, 2024 -- The Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona Pharma plc (Nasdaq: VRNA) as the development and manufacturing partner
Ritedose Pharmaceuticals Continues Tradition of Giving Back – Increases its Annual Donation to Unprecedented Amount of 1 Million Doses of Respiratory Medications to Dispensary of Hope for Low-income and Chronically lll Patients
COLUMBIA, S.C., August 12, 2024 – Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces today that it will donate 1 Million (1M) doses to the national charitable medication distributor, Dispensary of Hope,
Ritedose Named Top 2023 Fundraiser by the American Heart Association
COLUMBIA, S.C. July 29, 2024 – Working together, The Ritedose Corporation (Ritedose) employees raised more than $77,000 during the company’s annual Field Day event this spring in support of the American Heart Association. Additionally, the Association recognized Ritedose as the #1 Field Day company in the nation for 2023.
Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand for Ophthalmic and Respiratory Medications
COLUMBIA, S.C. June 20, 2024 – The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces a significant expansion of its production capabilities to meet the demand for ophthalmic and respiratory medications.
Ritedose Pharmaceuticals Launches <em>Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml)</em>
COLUMBIA, S.C. (August 24, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, launched a new sterile unit dose generic product, Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml). The single-dose vial product joins a range of other inhalation solutions produced by Ritedose Pharmaceuticals and is available in cartons
Ritedose Launches <em>Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL)</em> to Meet National Drug Shortage
COLUMBIA, S.C. (May 9, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose vial product, Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL). It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose
Ritedose Reaches Milestone with Asset Purchase <br><em>Becomes largest generic drug maker of its kind</em>
COLUMBIA, S.C.—The Ritedose Corporation, LLC now offers the most complete nebulized inhalation drug portfolio in the industry with the purchase of the Arformoterol Tartrate asset from PAI Pharma of Greenville, S.C.
Novo Holdings to acquire Ritedose: <br><em>Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire Ritedose from AGIC Capital and Humanwell.</em>
COPENHAGEN, Denmark, Jan. 4, 2022 /PRNewswire/ – Founded in 1995 and headquartered in Columbia, S.C., The Ritedose Corporation (“Ritedose”) is a leading sterile pharmaceutical manufacturer, specialising in the use of blow-fill-seal (BFS) technology. Ritedose provides outsourced development and manufacturing of ophthalmology drugs, respiratory drugs, and vaccines.
Recent Comments